Long-term Borrowing - Additional Information (Details) - USD ($) $ in Thousands |
6 Months Ended | |||||
|---|---|---|---|---|---|---|
Jan. 11, 2026 |
Jun. 27, 2025 |
Jun. 28, 2024 |
Sep. 05, 2023 |
Jun. 30, 2026 |
Dec. 31, 2025 |
|
| Short-Term Debt [Line Items] | ||||||
| Amendment, description | On January 11, 2026, the Company entered into the Third Amendment, which, among other things, (i) extended the draw period of Term Loan A to January 31, 2027, (ii) extended the draw period of Term Loan B to January 31, 2027, (iii) extended the draw period of Term Loan C to January 31, 2027, and (iv) extended the maturity date to January 1, 2029 ("Maturity Date"). Based on the occurrence of specified (a) development milestones related to the pivotal Phase 3 OPERA-01 clinical trial of palazestrant or (b) receipt of proceeds from capital financing, the draw period of Term Loan B and Term Loan C may be further extended to July 31, 2027, and the Maturity Date may be further extended to July 1, 2029.On July 1, 2026, the Company entered into the Fourth Amendment, which, among other things, added Olema Oncology International Limited as a secured guarantor under the Loan Agreement. | |||||
| Long-term borrowing | $ 3,000 | $ 3,000 | ||||
| Maximum | Other Income | ||||||
| Short-Term Debt [Line Items] | ||||||
| Interest expense | $ 100 | |||||
| Senior Secured Loan Facility | ||||||
| Short-Term Debt [Line Items] | ||||||
| Term of loan agreement | 4 years | |||||
| Aggregate principal amount | $ 50,000 | $ 50,000 | ||||
| Amount available for draw down, Private placement. | 25,000 | |||||
| Amount available for draw down, Lenders discretion | $ 25,000 | |||||
| Maturity date | Aug. 01, 2027 | |||||
| Interest rate | 6.00% | |||||
| Incremental interest rate at the event of default | 3.00% | |||||
| Amendment of Original Loan Agreement | ||||||
| Short-Term Debt [Line Items] | ||||||
| Aggregate principal amount | 100,000 | |||||
| Amount available for draw down, Lenders discretion | $ 50,000 | |||||
| Maturity date | Jan. 01, 2029 | Jan. 15, 2026 | Jul. 01, 2028 | |||
| Amount currently available for draw down | $ 25,000 | |||||
| Amount available for draw down upon achieving certain milestones related to execution of first line pivotal phase 3 | $ 25,000 | |||||
| Amendment of Original Loan Agreement | Term Loan A | ||||||
| Short-Term Debt [Line Items] | ||||||
| Maturity date | Jan. 31, 2027 | |||||
| Amendment of Original Loan Agreement | Term Loan B | ||||||
| Short-Term Debt [Line Items] | ||||||
| Maturity date | Jan. 31, 2027 | |||||
| Amendment of Original Loan Agreement | Term Loan C | ||||||
| Short-Term Debt [Line Items] | ||||||
| Maturity date | Jan. 31, 2027 |